



Alexion Pharmaceuticals Soliris(TM) (Eculizumab) data to be Presented at 2006 American Society of Hematology (ASH) Annual Meeting

CHESHIRE, Conn., Dec. 8 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that data relating to Soliris(TM) (eculizumab) for patients with paroxysmal nocturnal hemoglobinuria (PNH) will be presented at the 2006 ASH Annual Meeting in Orlando, Florida, December 9th to 12th by leading investigators in the Soliris(TM) (eculizumab) PNH clinical studies.

The following abstracts will be presented in oral sessions:

- "The Terminal Complement Inhibitor Eculizumab Reduces Thrombosis in Patients with Paroxysmal Nocturnal Hemoglobinuria" Dr. Peter Hillmen et al. Time: Sunday, December 10th at 5:00pm Room 315
- "Treatment with the Terminal Complement Inhibitor Eculizumab Improves Anemia in Patients with Paroxysmal Nocturnal Hemoglobinuria: Phase III TRIUMPH Study Results" Dr. Jorg Schubert et al. Time: Sunday, December 10th at 5:15pm Room 315 The following abstracts will be presented in poster sessions:
- "Safety and Efficacy of the Terminal Complement Inhibitor Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: SHEPHERD Phase III Clinical Study" Poster # 99-I Dr. Neal S. Young et al. Time: Saturday, December 9th at 9:00am Hall E-1
- "Blockade of Intravascular Hemolysis in PNH with the Terminal Complement Inhibitor Eculizumab Unmasks Low-Level Hemolysis Potentially Occurring through C3 Opsonization" Poster #100-I Dr. Anita Hill et al. Time: Saturday, December 9th at 9:00am Hall E-1